Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2021 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease | Chuang W.-L.; Hu T.-H.; Buggisch P.; Moreno C.; Su W.-W.; Biancone L.; Camargo M.; Hyland R.; Lu S.; Kirby B.J.; Dvory-Sobol H.; Osinusi A.; Gaggar A.; Peng C.-Y.; CHEN-HUA LIU ; Sise M.E.; Mangia A. | The American journal of gastroenterology | 7 | 6 | |
2020 | Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials | Asahina Y.; CHUN-JEN LIU ; Gane E.; Itoh Y.; Kawada N.; Ueno Y.; Youn J.; Wang C.-Y.; Llewellyn J.; Matsuda T.; Gaggar A.; Mo H.; Dvory-Sobol H.; Crans G.; Chuang W.-L.; PEI-JER CHEN ; Enomoto N. | Hepatology Research | 6 | 6 |